Natera (NASDAQ:NTRA) Insider John Fesko Sells 3,594 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 3,594 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $231.02, for a total transaction of $830,285.88. Following the sale, the insider directly owned 178,081 shares of the company’s stock, valued at $41,140,272.62. The trade was a 1.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

John Fesko also recently made the following trade(s):

• On Wednesday, January 28th, John Fesko sold 928 shares of Natera stock. The stock was sold at an average price of $237.66, for a total transaction of $220,548.48.
• On Tuesday, January 27th, John Fesko sold 784 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $188,575.52.
• On Wednesday, January 21st, John Fesko sold 339 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $79,665.00.
• On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $4,179,780.44.

Natera Stock Down 9.7%

Shares of NASDAQ:NTRA opened at $205.61 on Thursday. The business has a fifty day moving average of $234.95 and a two-hundred day moving average of $195.74. The stock has a market cap of $28.44 billion, a P/E ratio of -89.79 and a beta of 1.64. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period in the previous year, the firm posted ($0.26) EPS. The company’s revenue was up 34.7% compared to the same quarter last year. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera submitted a Premarket Approval (PMA) to the FDA for Signatera CDx to detect minimal residual disease (MRD) in bladder cancer after positive phase‑3 results — a regulatory win that could create a companion diagnostic revenue stream and improve clinical adoption/reimbursement if approved. Read More.
• Neutral Sentiment: Multiple non‑executive insiders also sold shares this week (Solomon Moshkevich and John Fesko each trimmed small single‑digit percentages of their holdings). These appear to be modest, routine dispositions versus strategic exits but add to selling pressure. Read More.
• Negative Sentiment: CEO Steven Chapman sold 85,299 shares on Feb 2 (~40% reduction in his holding) for a proceeds block of roughly $19.7M — a material insider disposition that investors often view negatively. Read More.
• Negative Sentiment: Additional executive sales this week: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), each trimming double‑digit or mid‑single digit ownership percentages — reinforcing near‑term downward pressure on the stock. Read More. Read More.

Hedge Funds Weigh In On Natera

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Horizon Investments LLC raised its stake in shares of Natera by 22.0% in the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 44 shares in the last quarter. Sound Income Strategies LLC raised its position in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares in the last quarter. Savvy Advisors Inc. raised its position in Natera by 3.1% in the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares in the last quarter. Siemens Fonds Invest GmbH boosted its stake in shares of Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after buying an additional 54 shares during the period. Finally, First Horizon Corp increased its stake in shares of Natera by 7.3% during the fourth quarter. First Horizon Corp now owns 931 shares of the medical research company’s stock worth $213,000 after buying an additional 63 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on NTRA. TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Citigroup initiated coverage on Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective for the company. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. BNP Paribas Exane upgraded shares of Natera to a “hold” rating and set a $172.00 price target for the company in a research report on Monday, October 27th. Finally, Piper Sandler boosted their price target on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.